May 12, 2010
The PXE Mouse Model and Magnesium
Research on pseudoxanthoma elasticum using knockout (KO) mice models has continued, and there are three interesting studies to report.

May 12, 2010
Retinal Treatments
There is a great deal more hope for individuals affected by pseudoxanthoma elasticum (PXE) when they experience choroidal neovascularization (CNV) than there has been in prior decades.  

May 11, 2010
PXE International BioBank Is World's Largest Repository of Pseudoxanthoma Elasticum Biological and Clinical Information
The PXE International BioBank, established in 1995, was the first lay-managed and -organized BioBank in the world, and continues to lead the way in novel infrastructure and aggressive dissemination.

May 11, 2010
UK's NHS Looking into Avastin® As Treatment for Wet AMD
There are reports that the UK´s National Health Service (NHS) “is looking into if it should break with convention and recommend the use of an unlicensed treatment for patients at risk of blindness.”

May 10, 2010
NIH Launches Therapeutics for Rare and Neglected Diseases (TRND) Program
In 2009 the National Institutes of Health (NIH) dedicated $24 million to launch the first integrated, drug development pipeline to produce new treatments for rare and neglected diseases.

March 8, 2010
Circulating Fetuin-A Counteracts Tissue Mineralization in PXE Mouse
Dr. Uitto's group reports in a January 2010 article that Fetuin-A circulating in the blood of the PXE mouse reduces the amount of tissue mineralization taking place.